Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase Ia trial of APD-811

Trial Profile

A phase Ia trial of APD-811

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ralinepag (Primary)
  • Indications Pulmonary hypertension
  • Focus Adverse reactions
  • Sponsors Arena Pharmaceuticals
  • Most Recent Events

    • 01 Jun 2017 New trial record
    • 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
    • 16 May 2017 According to an Arena Pharmaceuticals media release, data from this trial will be presented at the American Thoracic Society (ATS) 2017 International Conference.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top